NVDA
NVIDIA
-- 139.558 TSLA
Tesla
-- 417.040 PLTR
Palantir
-- 71.894 RGTI
Rigetti Computing
-- 6.8931 SMCI
Super Micro Computer
-- 38.230 
Update
$Terns Pharmaceuticals (TERN.US)$ Terns Pharmaceuticals Announces Positive Early Data From Phase 1 CARDINAL Trial of TERN-701 for Chronic Myeloid Leukemia
GlobeNewswire· 7 mins ago
Compelling molecular responses starting at lowest dose level in heavily pre-treated patients with high baseline BCR-ABL transcript levels
Encouraging safety profile with no dose limiting toxicities, adverse event-related treatment discontinuations, or dose reductions across three dose escalation cohorts
High levels of target coverage achieved with once daily dosing at all doses
Completion of dose escalation and initiation of dose expansion expected in 1H25
Additional efficacy data expected in 4Q25, including longer term major molecular response (MMR) rates
Company to host webcast at 8:00 am ET today
GlobeNewswire· 7 mins ago
Compelling molecular responses starting at lowest dose level in heavily pre-treated patients with high baseline BCR-ABL transcript levels
Encouraging safety profile with no dose limiting toxicities, adverse event-related treatment discontinuations, or dose reductions across three dose escalation cohorts
High levels of target coverage achieved with once daily dosing at all doses
Completion of dose escalation and initiation of dose expansion expected in 1H25
Additional efficacy data expected in 4Q25, including longer term major molecular response (MMR) rates
Company to host webcast at 8:00 am ET today
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment